LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The University of Texas Health Science Center at San Antonio
Taproot Health
Wake Forest University Health Sciences
Stanford University
Mannkind Corporation